Researchers launch study to measure effects of new rheumatologic agent

243
Secukinumab

Researchers at Hospital for Special Surgery (New York, USA) have launched a pilot study to see how a rheumatologic agent that treats several related autoimmune disorders affects the skeleton.

The two-year study, led by Susan M Goodman (Hospital for Spinal Surgery, New York, USA), will look at the effect on bone of secukinumab in men and women with ankylosing spondylitis (AS). Patients with AS, the prototypical form of spondyloarthritis, develop abnormal bone spurs called syndesmophytes. These growths can fuse vertebrae together, leading to loss of motion, pain and stiffness in the spine.

Despite the overactive growth of bone, people with spondyloarthritis often suffer from osteoporosis, a condition marked by fragile skeletons vulnerable to fracture. Studies have estimated the prevalence of the bone disorder at as high as 25% for these patients—more than double the 10% prevalence in the general population. Osteoporosis and low bone mass affect an estimated 44 million men and women in the USA, according to the International Osteoporosis Foundation.

The reason for the paradox: Although these patients produce more of one type of bone (cortical bone), which makes up the outside of the skeleton, the interior or trabecular bone is abnormally weak. As a result, their spines gradually become prone to small fractures that can lead to crippling changes in posture and significant pain and discomfort.

Although patients with AS and related disorders can take medication, such as bisphosphonates, calcium and vitamin D, to prevent fractures, they typically do not respond well to these therapies—and not as well as people with other autoimmune diseases.

Secukinumab belongs to a new class of monoclonal antibodies to treat autoimmune diseases. The FDA approved the drug in 2015 for adult patients with moderate to severe plaque psoriasis, and in 2016 it expanded that approval for adult patients to include AS and psoriatic arthritis. The drug specifically targets an immune protein called interleukin- 17A (IL-17A). Anti-IL17 antibodies may protect against bone loss in two ways: by suppressing the function of bone-resorbing cells called osteoclasts, and promoting the activity of bone-forming cells called osteoblasts.

Novartis is providing funding for the research.

(Visited 44 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here